CVKD (Cadrenal Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cadrenal Therapeutics Other Stockholders Equity?

Cadrenal Therapeutics's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $-0.00 Mil.

Cadrenal Therapeutics's quarterly Other Stockholders Equity declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) and declined from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($-0.00 Mil).

Cadrenal Therapeutics's annual Other Stockholders Equity declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil) but then increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil).

Cadrenal Therapeutics Other Stockholders Equity Historical Data

The historical data trend for Cadrenal Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadrenal Therapeutics Other Stockholders Equity Chart

Cadrenal Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Other Stockholders Equity

Cadrenal Therapeutics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial							-	-	-	-	-

Cadrenal Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Cadrenal Therapeutics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Cadrenal Therapeutics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadrenal Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadrenal Therapeutics Inc (NAS:CVKD) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082

Website

https://www.cadrenal.com

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Executives

John Raymond Murphy	director	233 S PATTERSON AVE, SPRINGFIELD MO 65802
Quang X Pham	director, 10 percent owner, officer: CEO and Chairman	89 MELROSE DRIVE, MISSION VIEJO CA 92692
Robert Lisicki	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Douglas W Losordo	officer: Chief Medical Officer	13 FOX MEADOW RD, SCARSDALE NY 10583
Steven Zelenkofske	director	120 MOUNTAIN VIEW BOULEVARD, BASKING RIDGE NJ 07920
Matthew K Szot	officer: Chief Financial Officer	802 NORTH DOUTY STREET, HANFORD CA 93230
Glynn Wilson	director	2483 NE JULEP STREET, ISSAQUAH WA 98029